2009 34(9)(Oncology suppl):3-11.ĪBSTRACT : Intravenous (IV) chemotherapeutic medications have the potential to cause extravasation injury or tissue necrosis at the site of administration. Where exposure to cyanide has occurred in pregnancy, enhanced antenatal monitoring may be warranted and discussion with UKTIS is recommended in all cases.US Pharm. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments. However, other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Where occupational exposure is unavoidable, precautions should be taken to ensure that exposure is well within the recommended exposure limits and not associated with toxic symptoms.Įxposure to sodium thiosulfate at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. If sodium thiosulfate is required in the management of cyanide poisoning during pregnancy, treatment should not be withheld on account of pregnancy.Īs with all chemicals, unnecessary exposure to sodium thiosulfate should be avoided. Improved maternal and fetal outcomes have been demonstrated when sodium thiosulfate was administered in the treatment of cyanogenic compound exposure in pregnant ewes.

The available animal data, although limited, have not demonstrated teratogenic effects for sodium thiosulfate.

There are no human pregnancy exposure data regarding the fetal effects of sodium thiosulfate exposure.

Sodium thiosulfate is an inorganic reducing agent used in commercial/industrial processes and as an antidote for cyanide poisoning.

Sodium thiosulfate antidote